Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424515 · ClinicalTrials.gov registry record · Phase 2
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
A Phase 2 study of Mucosal Melanoma and Acral/Lentiginous Melanoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT00424515 is a Phase 2 study of Mucosal Melanoma and Acral/Lentiginous Melanoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants, below the 152-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (84% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00424515, a Phase 2 study of Mucosal Melanoma and Acral/Lentiginous Melanoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate how effective imatinib (Gleevec) is in treating acral/lentiginous and mucosal melanoma which has spread to other parts of the body in patients who's disease carries a c-kit mutation. Imatinib is a protein-kinase inhibitor. It is believed that imatinib may be effective in blocking signals on certain cancer cells which allow the malignant cells to multiply and spread.
Conditions Studied
Interventions
- DRUG Imatinib
Study Locations (5)
Colorado
- University of Colorado at Denver Health Sciences Center - Denver
Florida
- H. Lee Moffitt Cancer Center - Tampa
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424515
The ClinicalTrials.gov registry entry for NCT00424515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (84% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mucosal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Imatinib is the first listed.
NCT00424515 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00424515 about?
NCT00424515 is a clinical study titled "Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma". The purpose of this study is to evaluate how effective imatinib (Gleevec) is in treating acral/lentiginous and mucosal melanoma which has spread to other parts of the body in patients who's disease carries a c-kit mutation. Imatinib is a protein-kinase inhibitor. It is believed that imatinib may be ...
What is the current status of trial NCT00424515?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2006-07. Estimated completion is 2011-07.
What conditions does trial NCT00424515 study?
This clinical trial studies the following conditions: Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas.
What interventions are being tested in trial NCT00424515?
The interventions under investigation include: Imatinib (DRUG).
Who is sponsoring clinical trial NCT00424515?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00424515 being conducted?
This trial has 5 study locations across Colorado, Florida, Illinois, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucosal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
RECRUITING · Phase 2
-
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.